These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 19581933)
1. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Gualberto A; Pollak M Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933 [TBL] [Abstract][Full Text] [Related]
2. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Gualberto A; Pollak M Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769 [TBL] [Abstract][Full Text] [Related]
3. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Ozkan EE Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884 [TBL] [Abstract][Full Text] [Related]
4. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Gridelli C; Rossi A; Bareschino MA; Schettino C; Sacco PC; Maione P Expert Opin Investig Drugs; 2010 May; 19(5):631-9. PubMed ID: 20367288 [TBL] [Abstract][Full Text] [Related]
5. Figitumumab (CP-751,871) for cancer therapy. Gualberto A Expert Opin Biol Ther; 2010 Apr; 10(4):575-85. PubMed ID: 20175655 [TBL] [Abstract][Full Text] [Related]
6. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169 [TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Heidegger I; Massoner P; Sampson N; Klocker H Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734 [TBL] [Abstract][Full Text] [Related]
8. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Gao J; Chang YS; Jallal B; Viner J Cancer Res; 2012 Jan; 72(1):3-12. PubMed ID: 22215692 [TBL] [Abstract][Full Text] [Related]
9. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Yap TA; Olmos D; Molife LR; de Bono JS Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167 [TBL] [Abstract][Full Text] [Related]
10. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857 [TBL] [Abstract][Full Text] [Related]
12. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Hofmann F; García-Echeverría C Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020 [TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Buck E; Mulvihill M Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886 [TBL] [Abstract][Full Text] [Related]
14. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375 [TBL] [Abstract][Full Text] [Related]
15. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Zha J; Lackner MR Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853 [TBL] [Abstract][Full Text] [Related]
16. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788 [TBL] [Abstract][Full Text] [Related]
17. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Pollak M Clin Cancer Res; 2012 Jan; 18(1):40-50. PubMed ID: 22215905 [TBL] [Abstract][Full Text] [Related]
18. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208 [TBL] [Abstract][Full Text] [Related]
19. [Targeting insulin-like growth factors in the treatment of cancer]. Moro-Sibilot D; Coudurier M; Lantuejoul S Rev Mal Respir; 2010 Oct; 27(8):959-63. PubMed ID: 20965410 [TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Hartog H; Wesseling J; Boezen HM; van der Graaf WT Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]